Table 2.
Response by Disease Status
| PSC-MEC
|
MEC
|
All Patients
|
||||
|---|---|---|---|---|---|---|
| Clinical Subgroup | No. of Patients | CR % | No. of Patients | CR % | No. of Patients | CR % |
| Prior intensive chemotherapy | ||||||
| First relapse < 6 months | 14 | 7 | 15 | 13 | 29 | 10 |
| Relapse after BMT | 8 | 25 | 8 | 25 | 16 | 25 |
| ≥Two relapses | 5 | 20 | 3 | 33 | 8 | 25 |
| Refractory AML | 19 | 5 | 17 | 18 | 36 | 11 |
| Subtotal (69% patients) | 46 | 11 | 43 | 19 | 89 | 15* |
|
| ||||||
| No prior intensive chemotherapy | ||||||
| Secondary AML | 13 | 39 | 11 | 36 | 24 | 38 |
| High-risk MDS | 7 | 14 | 9 | 44 | 16 | 31 |
| Subtotal (31% patients) | 20 | 30 | 20 | 40 | 40 | 35* |
|
| ||||||
| Total | 66 | 17† | 63 | 25† | 129 | 21 |
NOTE. Underlines separate individual categories from the subtotals and totals of each group.
Abbreviations: PSC-MEC, valspodar plus mitoxantrone, etoposide, and cytarabine; MEC, mitoxantrone, etoposide, and cytarabine; CR, complete remission; BMT, bone marrow transplantation; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome.
*
P = .018 by univariate analysis;
P = .045 by multivariate analysis.
†
P = not significant.